Skip to content
Artwork for Beginner's Mind
BusinessEntrepreneurshipInvestingTechnology

Beginner's Mind

Christian Soschner

Blueprints for Builders and Investors

Hosted by Christian Soschner


From pre-seed to post-IPO, every company—especially in deep tech, biotech, AI, and climate tech—lives or dies by the frameworks it follows.


On Beginner’s Mind, Christian Soschner uncovers the leadership principles behind the world’s most impactful companies—through deep-dive interviews, strategic book reviews, and patterns drawn from history’s greatest business, military, and political minds.


With over 250 interviews, panels, and livestreams, the show ranks in the Top 10% globally—and is recognized as the #1 deep tech podcast. 


With 35+ years across M&A, company building, board roles, business schools, ultrarunning, and martial arts, Christian brings a rare lens:


What it really takes to turn breakthrough science into business—how to grow it, lead it, and shape the world around it.


🎙 Expect each episode to deliver:

  • Founder & Investor Blueprints: How breakthrough technologies scale from lab to IPO
  • Historical & Biographical Frameworks: Timeless playbooks from the world's great builders
  • Leadership & Communication Mastery: Tools to inspire, persuade, and lead at scale


Whether you're building the next biotech success, investing in AI, or leading a climate tech company through hypergrowth—this podcast gives you the edge.


Listen in. Apply what matters. Build companies that last.


📬 Join the newsletter & community: https://lsg2g.substack.com/

Play
  • 22 episodes
  • fortnightly
  • Avg 1 hr 21 min
  • English

Support the show

Goes straight to the publisher. podnod takes nothing.

Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.
  • S6 · E19
    Oct 28, 2025 · 2 hr 7 min

    EP 165 – Jason Foster: 153 Rejections Later — What Every Founder Must Learn About Resilience

    Most founders dream of raising millions. Few survive the 153 “no’s” it takes to get there. Behind every biotech breakthrough lies exhaustion — late-night calls, failed rounds, and investors who walk away at the finish line. What separates the ones who make it isn’t luck or timing — it’s resilience built into process. In this episode, Jason Foster, CEO of Ori Biotech, shares how he transformed relentless rejection into a billion-dollar trajectory. From rebuilding cell-therapy manufacturing to leading global teams through economic storms, Jason reveals how founders can systematize grit, master storytelling, and survive when everything seems to fall apart. You’ll learn how to navigate fundraising winters, why leadership begins with self-care, and how to build companies that endure long after the hype fades. If you’ve ever doubted your path as a builder, this conversation will remind you that resilience is not a trait — it’s a practice. 💡 What You’ll Learn in This Episode 1️⃣ The real reason most founders fail long before capital runs out 2️⃣ How to turn rejection into momentum using process and habit 3️⃣ Why storytelling is the most underrated skill in biotech leadership 4️⃣ How resilience and self-care directly drive performance and valuation 5️⃣ The mindset that separates enduring companies from short-term success 👤 About Jason Foster Jason Foster is the CEO of Ori Biotech, a leading innovator transforming cell and gene therapy manufacturing. With 20+ years in global health, he has raised over $140M, led companies through IPO-level growth, and serves as a mentor and investor to emerging founders in life sciences. His mission: make advanced therapies accessible to every patient, everywhere. 💬 Quotes That Might Change How You Think (00:14:09) “There are cures for cancer today, but patients can’t reach them — access must change.” (00:37:22) “The science is extraordinary — but if we can’t make it at scale, it means nothing.” (01:22:17) “Purpose, not money, drives talent to transform lives through innovation.” (01:46:17) “Fundraising is a war of attrition — constant rejection tests your resilience more than your idea.” (02:02:16) “You only have to get up one more time than you’re knocked down.” 🧭 Timestamps to Explore (00:02:00) Embracing Hard Challenges — How Biotech Founders Build Resilience That Lasts (00:13:40) The Unacceptable Truth: Cures Exist, Yet Patients Still Can’t Access Them (00:26:23) Navigating Cultures — What European and American Biotech Leaders Can Learn From Each Other (00:32:52) Why Great Science Isn’t Enough Without Commercial Viability (00:39:19) Revolutionizing Cell Therapy Manufacturing — The Seven-Day Bottleneck Explained (00:50:11) Automation and Digitization — Unlocking Scalable Patient Access in Cell and Gene Therapy (01:09:30) Rethinking Capacity Utilization — Making Regional Biotech Manufacturing Centers Work (01:14:27) Mass Personalization — The Future Delivery Model for Advanced Therapies (01:23:00) Purpose-Driven Talent — The Secret to Retaining Top Biotech Performers (01:32:18) Fundraising as a War of Attrition — Building Vision Alignment With Investors (01:39:14) Building Investor Trust Before You Need It — A Founder’s Long Game (01:47:23) Resilience Transforms Rejection Into Triumph — Lessons From 153 Investor “No’s” 🎙️ Beginner’s Mind Top 10% globally. The leading podcast for founders, investors, and policymakers shaping the future of biotech and innovation. Send us Fan Mail Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now. Support the show Join the Podcast Newsletter: Link

    • Transcript
  • S6 · E18
    Oct 3, 2025 · 2 hr 20 min

    EP 164 - Kat Kozyrytska: AI in Pharma Is a Yesterday Problem – Why Ethical Frameworks Can’t Wait

    Imagine waking up to find your company’s most valuable IP leaked—not by hackers, but by the very AI tools you trusted. This isn’t a distant scenario; it’s happening inside pharma and biotech right now. And the cost isn’t just financial—it’s patient lives, broken trust, and an industry on the edge of losing credibility. In this episode, Kat Kozyrytska shares how leaders can act before invisible risks become catastrophic. From her personal journey in post-Soviet Ukraine to building frameworks in global biotech, Kat reveals why “yesterday problems” with AI demand urgent attention today. You’ll learn how data privacy failures propagate quietly, why embedding organizational values into AI is essential, and how collaboration across companies can safeguard innovation and accelerate therapies. The future of biotech won’t be secured by hype or speed—but by trust, ethics, and the courage to act before it’s too late. 🎧 What You’ll Learn in This Episode 1️⃣ Why “yesterday problems” with AI in pharma are already costing billions 2️⃣ How data privacy failures silently erode trust, IP, and patient safety 3️⃣ The difference between collaboration and competition in biotech innovation 4️⃣ Why embedding organizational values into AI is no longer optional 5️⃣ The future of drug discovery, clinical trials, and manufacturing in an AI-first world 👤 About Kat Kozyrytska Kat Kozyrytska is the Founder of the Cell Therapy Manufacturability Program and a global thought leader at the intersection of biotech and AI. With roots in Ukraine and a career spanning MIT, Stanford, Thermo Fisher, Sartorius, and global biotech startups, she bridges technical depth with ethical foresight. 💬 Quotes That Might Change How You Think (00:14:50) "AI can amplify good or bad behaviors — the choice is ours." (00:38:14) "Discovering dark personalities is like learning Santa isn’t real — traumatic, but suddenly everything makes sense." (01:03:26) "AI speaks with absolute confidence, but confidence is not the same as truth." (01:20:22) "AI gives us a rare chance to embed ethics and values into innovation." (01:57:01) "If personalized therapies work better, we have an ethical duty to deliver them." 🧭 Timestamps to Explore (00:05:16) From Math to Medicine – Kat’s unexpected path from equations to biotech leadership (00:09:38) Inside a Nobel Lab – How neuroscience breakthroughs shaped her ethical lens (00:12:27) Shadow AI – Why biotech leaders can’t wait to govern hidden systems (00:23:03) Data Sharing Paradox – Collaboration vs confidentiality in pharma innovation (00:31:31) Neurobiology of Manipulation – How dark personalities exploit human trust (00:41:18) Hidden Privacy Risks – What your everyday data footprint really reveals (00:52:17) Soviet Control vs American Individualism – Lessons for AI governance today (00:57:30) The Danger of One Answer – Why converging on a single AI truth is risky (01:02:51) Confidence ≠ Expertise – Rethinking how we trust AI in science (01:18:16) Embedding Core Values – How leaders can align AI with human ethics (01:51:28) Breaking Down Silos – The future of collaborative drug discovery with AI (02:14:39) Biotech 2035 – Kat’s optimistic vision for an ethical AI future 🎙️ Beginner’s Mind Top 10% globally. The leading podcast for VCs, operators, and anyone obsessed with building what comes next. Send us Fan Mail Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now. Support the show Join the Podcast Newsletter: Link

    • Transcript
Showing 21–22 of 22 episodes